{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:34:32Z","timestamp":1791005672602,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T00:00:00Z","timestamp":1664755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T00:00:00Z","timestamp":1664755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008368","name":"Gigtforeningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008368","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Knud og Edith Eriksens Fond"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cannabis-based medicines are widely used in the treatment of a number of medical conditions. Unfortunately, cognitive disturbances are often reported as adverse events, although conversely, cognitive improvements have been reported. Hence, the objective of the present study was to identify, critically appraise and synthesise research findings on the potential impact of cannabis-based medicines on cognitive functioning.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Four databases (EMBASE, PsycINFO, PubMed and Scopus) were systematically searched. Studies were included if they provided findings on the impact of cannabis-based medicines in controlled settings on cognitive functioning measured by recognised cognitive tests in human adults. Study participants were required to be their own case-control, and neither studies on abuse, abstinences, patients with severe neurodegenerative diseases nor cancer-related pain conditions were included. Screening, risk of bias assessment and data extraction were conducted independently by two researchers. Findings were tabulated and synthesised by outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Findings<\/jats:title>\n                <jats:p>Twenty-three studies were included, comprising a total of <jats:italic>N<\/jats:italic> = 917. Eight studies used Sativex as the cannabis-based medicine two used Epidiolex, two other studies used sprays, three studies used gelatine capsules, five smoked cannabis, two other and finally one studied cannabis withdrawal. Fifteen studies reported non-significant findings; six reported cognitive impairments; one study found cognitive improvement and a single study found improvement following withdrawal. Thirteen studies had cognitive or neuropsychological functioning as the primary outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Due to a large heterogeneity and methodological limitations across studies, it is not possible to make any definite conclusions about the impact of cannabis-based medicines on cognitive functioning. However, the majority of high-quality evidence points in the direction that the negative impact of cannabis-based medicines on cognitive functioning is minor, provided that the doses of THC are low to moderate. On the other hand, long-term use of cannabis based medicines may still adversely affect cognitive functioning. In the studies that found impaired cognitive functioning to be significant, all of the test scores were either within the normal range or below what would be characterised as a neuropsychologically cognitive impairment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13643-022-02073-5","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T22:02:42Z","timestamp":1664834562000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["The effect of medical cannabis on cognitive functions: a systematic review"],"prefix":"10.1186","volume":"11","author":[{"given":"Anders","family":"Wieghorst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten Kaya","family":"Roessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Hendricks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9045-7500","authenticated-orcid":false,"given":"Tonny Elmose","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,3]]},"reference":[{"key":"2073_CR1","unstructured":"Trumble S. Timeline of State Marijuana Legalization Laws [website].\u00a0Washington, DC:\u00a0Third Way;\u00a02016.\u00a0https:\/\/www.thirdway.org\/. [updated April 19 2017]. Available from: https:\/\/www.thirdway.org\/infographic\/timeline-of-state-marijuana-legalization-laws."},{"issue":"3","key":"2073_CR2","first-page":"180","volume":"42","author":"MB Bridgeman","year":"2017","unstructured":"Bridgeman MB, Abazia DT. Medicinal cannabis: history, pharmacology, and implications for the acute care setting. P T. 2017;42(3):180\u20138.","journal-title":"P T"},{"issue":"24","key":"2073_CR3","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1001\/jama.2015.6358","volume":"313","author":"PF Whiting","year":"2015","unstructured":"Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456\u201373. https:\/\/doi.org\/10.1001\/jama.2015.6358.","journal-title":"JAMA"},{"issue":"2","key":"2073_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/phar.1187","volume":"33","author":"LM Borgelt","year":"2013","unstructured":"Borgelt LM, Franson KL, Nussbaum AM, Wang GS. The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy. 2013;33(2):195\u2013209.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"2073_CR5","first-page":"e78","volume":"64","author":"GM Allan","year":"2018","unstructured":"Allan GM, Finley CR, Ton J, Perry D, Ramji J, Crawford K, et al. Systematic review of systematic reviews for medical cannabinoids: pain, nausea and vomiting, spasticity, and harms. Can Fam Physician. 2018;64(2):e78\u201394.","journal-title":"Can Fam Physician"},{"issue":"10","key":"2073_CR6","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1097\/j.pain.0000000000001293","volume":"159","author":"E Stockings","year":"2018","unstructured":"Stockings E, Campbell G, Hall WD, Nielsen S, Zagic D, Rahman R, et al. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain. 2018;159(10):1932\u201354. https:\/\/doi.org\/10.1097\/j.pain.0000000000001293.","journal-title":"Pain"},{"key":"2073_CR7","doi-asserted-by":"publisher","first-page":"103338","DOI":"10.1016\/j.msard.2021.103338","volume":"57","author":"J Landrigan","year":"2022","unstructured":"Landrigan J, Bessenyei K, Leitner D, Yakovenko I, Fisk JD, Prentice JL. A systematic review of the effects of cannabis on cognition in people with multiple sclerosis. Mult Scler Relat Disord. 2022;57:103338.","journal-title":"Mult Scler Relat Disord"},{"issue":"9-10","key":"2073_CR8","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1017\/S1355617717000789","volume":"23","author":"R Gonzalez","year":"2017","unstructured":"Gonzalez R, Pacheco-Col\u00f3n I, Duperrouzel JC, Hawes SW. Does cannabis use cause declines in neuropsychological functioning? A review of longitudinal studies. J Int Neuropsychol Soc. 2017;23(9-10):893\u2013902. https:\/\/doi.org\/10.1017\/S1355617717000789.","journal-title":"J Int Neuropsychol Soc"},{"key":"2073_CR9","doi-asserted-by":"publisher","first-page":"105990","DOI":"10.1016\/j.clineuro.2020.105990","volume":"196","author":"G Alessandria","year":"2020","unstructured":"Alessandria G, Meli R, Infante MT, Vestito L, Capello E, Bandini F. Long-term assessment of the cognitive effects of nabiximols in patients with multiple sclerosis: a pilot study. Clin Neurol Neurosurg. 2020;196:105990. https:\/\/doi.org\/10.1016\/j.clineuro.2020.105990.","journal-title":"Clin Neurol Neurosurg"},{"issue":"9","key":"2073_CR10","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1093\/brain\/awz213","volume":"142","author":"A Feinstein","year":"2019","unstructured":"Feinstein A, Meza C, Stefan C, Staines RW. Coming off cannabis: a cognitive and magnetic resonance imaging study in patients with multiple sclerosis. Brain. 2019;142(9):2800\u201312. https:\/\/doi.org\/10.1093\/brain\/awz213.","journal-title":"Brain"},{"issue":"10","key":"2073_CR11","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1503\/cmaj.110837","volume":"184","author":"J Corey-Bloom","year":"2012","unstructured":"Corey-Bloom J, Wolfson T, Gamst A, Jin S, Marcotte TD, Bentley H, et al. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ. 2012;184(10):1143\u201350. https:\/\/doi.org\/10.1503\/cmaj.110837.","journal-title":"CMAJ"},{"issue":"7","key":"2073_CR12","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jpain.2015.03.008","volume":"16","author":"MS Wallace","year":"2015","unstructured":"Wallace MS, Marcotte TD, Umlauf A, Gouaux B, Atkinson JH. Efficacy of inhaled cannabis on painful diabetic neuropathy. J Pain. 2015;16(7):616\u201327.","journal-title":"J Pain"},{"issue":"6","key":"2073_CR13","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jpain.2007.12.010","volume":"9","author":"B Wilsey","year":"2008","unstructured":"Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2008;9(6):506\u201321.","journal-title":"J Pain"},{"issue":"6","key":"2073_CR14","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1212\/01.wnl.0000176753.45410.8b","volume":"65","author":"DJ Rog","year":"2005","unstructured":"Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65(6):812\u20139.","journal-title":"Neurology"},{"issue":"2","key":"2073_CR15","first-page":"1","volume":"1","author":"M Vachov\u00e1","year":"2014","unstructured":"Vachov\u00e1 M, Novotn\u00e1 A, Mares J, Tal\u00e1b R, Fiedler J, Lauder H, et al. A multicentre, double-blind, randomised, parallel-group, placebo-controlled study of effect of long-term sativexand# 174; treatment on cognition and mood of patients with spasticity due to multiple sclerosis. J Mult Scler (Foster City). 2014;1(2):1\u20138.","journal-title":"J Mult Scler (Foster City)"},{"issue":"4","key":"2073_CR16","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1191\/1352458504ms1048oa","volume":"10","author":"C Vaney","year":"2004","unstructured":"Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler. 2004;10(4):417\u201324.","journal-title":"Mult Scler"},{"key":"2073_CR17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.yebeh.2019.04.044","volume":"97","author":"RC Martin","year":"2019","unstructured":"Martin RC, Gaston TE, Thompson M, Ampah SB, Cutter G, Bebin EM, et al. Cognitive functioning following long-term cannabidiol use in adults with treatment-resistant epilepsy. Epilepsy Behav. 2019;97:105\u201310.","journal-title":"Epilepsy Behav"},{"issue":"7","key":"2073_CR18","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097.","journal-title":"PLoS Med"},{"key":"2073_CR19","doi-asserted-by":"publisher","first-page":"983","DOI":"10.3389\/fphar.2017.00983","volume":"8","author":"SA Gruber","year":"2018","unstructured":"Gruber SA, Sagar KA, Dahlgren MK, Gonenc A, Smith RT, Lambros AM, et al. The grass might be greener: medical marijuana patients exhibit altered brain activity and improved executive function after 3 months of treatment. Front Pharmacol. 2018;8:983. https:\/\/doi.org\/10.3389\/fphar.2017.00983.","journal-title":"Front Pharmacol"},{"key":"2073_CR20","doi-asserted-by":"publisher","unstructured":"Gruber SA, Sagar KA, Dahlgren MK, Racine MT, Smith RT, Lukas SE. Splendor in the grass? A pilot study assessing the impact of medical marijuana on executive function. Front Pharmacol. 2016;7(355). https:\/\/doi.org\/10.3389\/fphar.2016.00355.","DOI":"10.3389\/fphar.2016.00355"},{"issue":"3","key":"2073_CR21","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/j.1524-475X.2004.04006.x","volume":"1","author":"BH Thomas","year":"2004","unstructured":"Thomas BH, Ciliska D, Dobbins M, Micucci S. A process for systematically reviewing the literature: providing the research evidence for public health nursing interventions. Worldviews Evid Based Nurs. 2004;1(3):176\u201384. https:\/\/doi.org\/10.1111\/j.1524-475X.2004.04006.x.","journal-title":"Worldviews Evid Based Nurs"},{"issue":"1","key":"2073_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/WNF.0b013e3181633497","volume":"32","author":"M Aragona","year":"2009","unstructured":"Aragona M, Onesti E, Tomassini V, Conte A, Gupta S, Gilio F, et al. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clin Neuropharmacol. 2009;32(1):41\u20137.","journal-title":"Clin Neuropharmacol."},{"issue":"8","key":"2073_CR23","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.euroneuro.2017.05.005","volume":"27","author":"RE Cooper","year":"2017","unstructured":"Cooper RE, Williams E, Seegobin S, Tye C, Kuntsi J, Asherson P. Cannabinoids in attention-deficit\/hyperactivity disorder: A randomised-controlled trial. Eur Neuropsychopharmacol. 2017;27(8):795\u2013808.","journal-title":"Eur Neuropsychopharmacol."},{"issue":"4","key":"2073_CR24","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1191\/1352458504ms1082oa","volume":"10","author":"DT Wade","year":"2004","unstructured":"Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10(4):434\u201341.","journal-title":"Mult Scler."},{"issue":"14","key":"2073_CR25","first-page":"3127","volume":"20","author":"M Russo","year":"2016","unstructured":"Russo M, De Luca R, Torrisi M, Rifici C, Sessa E, Bramanti P, et al. Should we care about sativex-induced neurobehavioral effects? A 6-month follow-up study. Eur Rev Med Pharmacol Sci. 2016;20(14):3127\u201333.","journal-title":"Eur Rev Med Pharmacol Sci."},{"issue":"1","key":"2073_CR26","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/1352458518765649","volume":"25","author":"L Castelli","year":"2018","unstructured":"Castelli L, Prosperini L, Pozzilli C. Balance worsening associated with nabiximols in multiple sclerosis. Mult Scler. 2018;25(1):113\u20137. https:\/\/doi.org\/10.1177\/1352458518765649.","journal-title":"Mult Scler"},{"key":"2073_CR27","doi-asserted-by":"crossref","unstructured":"Metternich B, Wagner K, Geiger MJ, Hirsch M, Schulze-Bonhage A, Klotz KA. Cognitive and behavioral effects of cannabidiol in patients with treatment-resistant epilepsy. Epilepsy Behav. 2021;114:107558.","DOI":"10.1016\/j.yebeh.2020.107558"},{"issue":"8","key":"2073_CR28","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/ejp.1605","volume":"24","author":"S Almog","year":"2020","unstructured":"Almog S, Aharon-Peretz J, Vulfsons S, Ogintz M, Abalia H, Lupo T, et al. The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial. Eur J Pain. 2020;24(8):1505\u201316.","journal-title":"Eur J Pain"},{"issue":"1","key":"2073_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1191\/0269215503cr581oa","volume":"17","author":"DT Wade","year":"2003","unstructured":"Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil. 2003;17(1):21\u20139. https:\/\/doi.org\/10.1191\/0269215503cr581oa.","journal-title":"Clin Rehabil"},{"issue":"1","key":"2073_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1055\/s-2001-15191","volume":"34","author":"KR Muller-Vahl","year":"2001","unstructured":"Muller-Vahl KR, Koblenz A, Jobges M, Kolbe H, Emrich HM, Schneider U. Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance. Pharmacopsychiatry. 2001;34(1):19\u201324. https:\/\/doi.org\/10.1055\/s-2001-15191.","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"2073_CR31","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/sj.npp.1300047","volume":"28","author":"KR M\u00fcller-Vahl","year":"2003","unstructured":"M\u00fcller-Vahl KR, Prevedel H, Theloe K, Kolbe H, Emrich HM, Schneider U. Treatment of tourette syndrome with delta-9-tetrahydrocannabinol (\u0394 9-THC): no influence on neuropsychological performance. Neuropsychopharmacology. 2003;28(2):384\u20138.","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"2073_CR32","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jpain.2012.10.009","volume":"14","author":"B Wilsey","year":"2013","unstructured":"Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain. 2013;14(2):136\u201348.","journal-title":"J Pain"},{"issue":"10","key":"2073_CR33","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1513\/AnnalsATS.201803-198OC","volume":"15","author":"SJ Abdallah","year":"2018","unstructured":"Abdallah SJ, Smith BM, Ware MA, Moore M, Li PZ, Bourbeau J, et al. Effect of vaporized cannabis on exertional breathlessness and exercise endurance in advanced chronic obstructive pulmonary disease. A randomized controlled trial. Ann Am Thorac Soc. 2018;15(10):1146\u201358. https:\/\/doi.org\/10.1513\/AnnalsATS.201803-198OC.","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"2073_CR34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/CAD.0000000000000685","volume":"30","author":"G Bar-Sela","year":"2019","unstructured":"Bar-Sela G, Tauber D, Mitnik I, Sheinman-Yuffe H, Bishara-Frolova T, Aharon-Peretz J. Cannabis-related cognitive impairment: a prospective evaluation of possible influences on patients with cancer during chemotherapy treatment as a pilot study. Anticancer Drugs. 2019;30(1):91\u20137.","journal-title":"Anticancer Drugs"},{"key":"2073_CR35","doi-asserted-by":"publisher","first-page":"102708","DOI":"10.1016\/j.msard.2020.102708","volume":"48","author":"S Gustavsen","year":"2021","unstructured":"Gustavsen S, S\u00f8ndergaard H, Linnet K, Thomsen R, Rasmussen B, Sorensen P, et al. Safety and efficacy of low-dose medical cannabis oils in multiple sclerosis. Mult Scler Relat Disord. 2021;48:102708.","journal-title":"Mult Scler Relat Disord"},{"key":"2073_CR36","unstructured":"GW Pharma Ltd. Sativex oromucosal spray.\u00a02020. https:\/\/www.medicines.org.uk\/emc\/product\/602\/, www.medicines.org.uk.\u00a0 [updated 27 May 2020]."},{"key":"2073_CR37","unstructured":"GW Pharma Ltd. Epidyolex 100 mg\/ml oral solution. 2021. https:\/\/www.medicines.org.uk\/emc\/product\/10781\/, www.medicines.org.uk. [updated 02\/2021]."},{"issue":"11","key":"2073_CR38","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.jpain.2020.03.003","volume":"21","author":"MS Wallace","year":"2020","unstructured":"Wallace MS, Marcotte TD, Atkinson JH, Padovano HT, Bonn-Miller M. A secondary analysis from a randomized trial on the effect of plasma tetrahydrocannabinol levels on pain reduction in painful diabetic peripheral neuropathy. J Pain. 2020;21(11):1175\u201386. https:\/\/doi.org\/10.1016\/j.jpain.2020.03.003.","journal-title":"J Pain"},{"issue":"3","key":"2073_CR39","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/BF02214761","volume":"5","author":"RW Elwood","year":"1995","unstructured":"Elwood RW. The California verbal learning test: psychometric characteristics and clinical application. Neuropsychol Rev. 1995;5(3):173\u2013201. https:\/\/doi.org\/10.1007\/BF02214761.","journal-title":"Neuropsychol Rev"},{"issue":"4","key":"2073_CR40","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/arclin\/11.4.329","volume":"11","author":"RM Ruff","year":"1996","unstructured":"Ruff RM, Light RH, Parker SB, Levin HS. Benton controlled oral word association test: Reliability and updated norms. Arch Clin Neuropsychol. 1996;11(4):329\u201338.","journal-title":"Arch Clin Neuropsychol"},{"key":"2073_CR41","volume-title":"Handbook of normative data for neuropsychological assessment","author":"M Mitrushina","year":"2005","unstructured":"Mitrushina M, Boone KB, Razani J, D\u2019Elia LF. Handbook of normative data for neuropsychological assessment. New York: Oxford University Press; 2005."},{"issue":"1","key":"2073_CR42","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1076\/clin.12.1.43.1726","volume":"12","author":"RHB Benedict","year":"1998","unstructured":"Benedict RHB, Schretlen D, Groninger L, Brandt J. Hopkins verbal learning test \u2013 revised: normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol. 1998;12(1):43\u201355. https:\/\/doi.org\/10.1076\/clin.12.1.43.1726.","journal-title":"Clin Neuropsychol"},{"issue":"1","key":"2073_CR43","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.acn.2005.07.006","volume":"21","author":"TN Tombaugh","year":"2006","unstructured":"Tombaugh TN. A comprehensive review of the Paced Auditory Serial Addition Test (PASAT). Arch Clin Neuropsychol. 2006;21(1):53\u201376. https:\/\/doi.org\/10.1016\/j.acn.2005.07.006.","journal-title":"Arch Clin Neuropsychol"},{"issue":"6","key":"2073_CR44","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1176\/ajp.140.6.734","volume":"140","author":"R Katzman","year":"1983","unstructured":"Katzman R, Brown T, Fuld P, Peck A, Schechter R, Schimmel H. Validation of a short Orientation-Memory-Concentration Test of cognitive impairment. Am J Psychiatry. 1983;140(6):734\u20139. https:\/\/doi.org\/10.1176\/ajp.140.6.734.","journal-title":"Am J Psychiatry"},{"key":"2073_CR45","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3389\/fpsyg.2017.00557","volume":"8","author":"F Scarpina","year":"2017","unstructured":"Scarpina F, Tagini S. The stroop color and word test. Front Psychol. 2017;8:557.","journal-title":"Front Psychol"},{"key":"2073_CR46","volume-title":"A compendium of neuropsychological tests: administration, norms, and commentary","author":"E Strauss","year":"2006","unstructured":"Strauss E, Sherman EMS, Spreen O. A compendium of neuropsychological tests: administration, norms, and commentary. 3rd ed. New York: Oxford University Press; 2006.","edition":"3"},{"key":"2073_CR47","unstructured":"Lezak MD, Howieson DB, Loring DW, Hannay HJ, Fischer JS. Neuropsychological assessment. 4th ed. New York: Oxford University Press; 2004. p. xiv, 1016-xiv."},{"issue":"6","key":"2073_CR48","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1080\/13803390591004428","volume":"28","author":"W van der Elst","year":"2006","unstructured":"van der Elst W, van Boxtel MPJ, van Breukelen GJP, Jolles J. The letter digit substitution test: normative data for 1,858 healthy participants aged 24\u201381 from the Maastricht Aging Study (MAAS): influence of age, education, and sex. J Clin Exp Neuropsychol. 2006;28(6):998\u20131009. https:\/\/doi.org\/10.1080\/13803390591004428.","journal-title":"J Clin Exp Neuropsychol"},{"issue":"3","key":"2073_CR49","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1017\/S1355617709090626","volume":"15","author":"I S\u00e1nchez-Cubillo","year":"2009","unstructured":"S\u00e1nchez-Cubillo I, Peri\u00e1\u00f1ez JA, Adrover-Roig D, Rodr\u00edguez-S\u00e1nchez JM, R\u00edos-Lago M, Tirapu J, et al. Construct validity of the Trail Making Test: role of task-switching, working memory, inhibition\/interference control, and visuomotor abilities. J Int Neuropsychol Soc. 2009;15(3):438\u201350. https:\/\/doi.org\/10.1017\/S1355617709090626.","journal-title":"J Int Neuropsychol Soc"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-022-02073-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-022-02073-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-022-02073-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T22:04:57Z","timestamp":1664834697000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-022-02073-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,3]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2073"],"URL":"https:\/\/doi.org\/10.1186\/s13643-022-02073-5","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,3]]},"assertion":[{"value":"6 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"210"}}